Movement Alert｜Definium Therapeutics Rises 7.03% Overnight, DT120 Phase 3 Data Momentum Continues

Market Focus07-16

On July 16, Definium Therapeutics rose 7.03% overnight, trading at $48.87 per share, with turnover of $19,100.

The continued upward momentum is driven by the sustained positive market reaction to the company's core candidate DT120 orally disintegrating tablet achieving positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder. The trial met its primary endpoint and all key secondary efficacy endpoints, demonstrating statistically significant and clinically meaningful improvement over placebo.

Following the data readout, the company successfully closed an upsized $805 million public offering at $34 per share, with underwriters exercising their overallotment option in full. RBC Capital subsequently raised its price target from $36 to $57, maintaining an Outperform rating. With the current stock price still trading below that target, buying momentum has persisted. Additionally, the company initiated dosing in Ascend, its second pivotal Phase 3 trial for DT120 in MDD, with topline data expected next year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158920231?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 08:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158920231","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Definium Therapeutics Rises 7.03% Overnight, DT120 Phase 3 Data Momentum Continues","media":"Market Focus","content":"<p><p>On July 16, Definium Therapeutics rose 7.03% overnight, trading at $48.87 per share, with turnover of $19,100.</p><p>The continued upward momentum is driven by the sustained positive market reaction to the company's core candidate DT120 orally disintegrating tablet achieving positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder. The trial met its primary endpoint and all key secondary efficacy endpoints, demonstrating statistically significant and clinically meaningful improvement over placebo.</p><p>Following the data readout, the company successfully closed an upsized $805 million public offering at $34 per share, with underwriters exercising their overallotment option in full. RBC Capital subsequently raised its price target from $36 to $57, maintaining an Outperform rating. With the current stock price still trading below that target, buying momentum has persisted. Additionally, the company initiated dosing in Ascend, its second pivotal Phase 3 trial for DT120 in MDD, with topline data expected next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Definium Therapeutics Rises 7.03% Overnight, DT120 Phase 3 Data Momentum Continues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Definium Therapeutics Rises 7.03% Overnight, DT120 Phase 3 Data Momentum Continues\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 08:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, Definium Therapeutics rose 7.03% overnight, trading at $48.87 per share, with turnover of $19,100.</p><p>The continued upward momentum is driven by the sustained positive market reaction to the company's core candidate DT120 orally disintegrating tablet achieving positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder. The trial met its primary endpoint and all key secondary efficacy endpoints, demonstrating statistically significant and clinically meaningful improvement over placebo.</p><p>Following the data readout, the company successfully closed an upsized $805 million public offering at $34 per share, with underwriters exercising their overallotment option in full. RBC Capital subsequently raised its price target from $36 to $57, maintaining an Outperform rating. With the current stock price still trading below that target, buying momentum has persisted. Additionally, the company initiated dosing in Ascend, its second pivotal Phase 3 trial for DT120 in MDD, with topline data expected next year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFTX","symbol_name":"Definium Therapeutics","start_time":0,"source_url":"","article_id":"1158920231","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158920231","pubTimestamp":1784162901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, Definium Therapeutics rose 7.03% overnight, trading at $48.87 per share, with turnover of $19,100.The continued upward momentum is driven by the sustained positive market reaction to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFTX":"Definium Therapeutics"},"translate_title":"走势警报|Definium Therapeutics隔夜上涨7.03%，DT120 3期数据势头延续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":1},"content_text":"On July 16, Definium Therapeutics rose 7.03% overnight, trading at $48.87 per share, with turnover of $19,100.The continued upward momentum is driven by the sustained positive market reaction to the company's core candidate DT120 orally disintegrating tablet achieving positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder. The trial met its primary endpoint and all key secondary efficacy endpoints, demonstrating statistically significant and clinically meaningful improvement over placebo.Following the data readout, the company successfully closed an upsized $805 million public offering at $34 per share, with underwriters exercising their overallotment option in full. RBC Capital subsequently raised its price target from $36 to $57, maintaining an Outperform rating. With the current stock price still trading below that target, buying momentum has persisted. Additionally, the company initiated dosing in Ascend, its second pivotal Phase 3 trial for DT120 in MDD, with topline data expected next year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158920231","isCrawlerRequest":true}